Bulvas M, Chochola M, Herdová J, Sommerová Z, Urbanová R
IV. interní klinika 1. LF UK a VFN, Praha.
Cas Lek Cesk. 1996 Jul 14;135(14):445-9.
The condition of patients after percutaneous transluminal angioplasty is influenced among others by the subsequent development of restenoses and reocclusions. The objective of the submitted work was to assess whether oral administration of heparan sulphate can influence the development of restenoses after percutaneous transluminal angioplasty in the pelvic and femoropopliteal region.
102 patients (78 men and 24 women, age 42-86 years) were divided into four groups. Percutaneous transluminal angioplasty was performed either on account stenosis in the aortoiliac or femoropopliteal area. (The original number was 115 patients, 13 patients were eliminated: the reasons were technical failure of the intervention procedure, reocclusion, the patient was lost from records.) As antiaggregant the patients were given acetylsalicylic acid, 250 mg/day: patients included in the heparan group were given heparan sulphate (Hemovasal, Manetti and Roberts) 100 mg/day for a period of 3 - 4 months. As compared with controls, the patients treated with heparan sulphate had within the 3 - 4 month period a significantly longer claudication distance (p < 0.05), a higher Doppler index (p < 0.05) and maximal blood flow in the feet.
Heparan sulphate administration to patients after percutaneous transluminal angioplasty on account of stenosis of the aortoiliac or femoropopliteal area improves some angiological parameters which can suggest a slighter tendency of early restenosis.
经皮腔内血管成形术后患者的病情受再狭窄和再闭塞等后续发展情况的影响。本研究的目的是评估口服硫酸乙酰肝素是否会影响盆腔及股腘动脉区域经皮腔内血管成形术后再狭窄的发展。
102例患者（78例男性，24例女性，年龄42 - 86岁）被分为四组。根据腹主动脉 - 髂动脉或股腘动脉区域的狭窄情况进行经皮腔内血管成形术。（最初有115例患者，排除13例：原因包括介入手术技术失败、再闭塞、患者失访。）作为抗聚集剂，患者服用阿司匹林，250毫克/天；硫酸乙酰肝素组的患者服用硫酸乙酰肝素（Hemovasal，马内蒂和罗伯茨公司生产），100毫克/天，持续3 - 4个月。与对照组相比，服用硫酸乙酰肝素的患者在3 - 4个月内的跛行距离明显更长（p < 0.05），多普勒指数更高（p < 0.05），足部最大血流量更大。
对于因腹主动脉 - 髂动脉或股腘动脉区域狭窄而行经皮腔内血管成形术的患者，服用硫酸乙酰肝素可改善一些血管学参数，这可能表明早期再狭窄的倾向较小。
